Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)

Barclays analyst Peter Lawson maintained a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $3.90.

Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, MacroGenics, and Fate Therapeutics. According to TipRanks, Lawson has an average return of 6.1% and a 43.86% success rate on recommended stocks.

Currently, the analyst consensus on Fate Therapeutics is a Hold with an average price target of $7.20.

FATE market cap is currently $443.9M and has a P/E ratio of -2.03.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fate Therapeutics (FATE) Company Description:

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.